Next Article in Journal
N,N-bis(2-quinolinylmethyl)benzylamine
Next Article in Special Issue
7-Bromo-[1,2,5]selenadiazolo[3,4-d]pyridazin-4(5H)-one
Previous Article in Journal
Synthesis of Polar Aromatic Substituted Terminal Alkynes from Propargyl Amine
Previous Article in Special Issue
4-(7-Bromobenzo[d][1,2,3]thiadiazol-4-yl)morpholine
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Short Note

Methyl 2-Amino-4-[1-(tert-butoxycarbonyl)azetidin-3-yl]-1,3-selenazole-5-carboxylate

by
Karolina Dzedulionytė
1,*,
Paulina Voznikaitė
2,
Aurimas Bieliauskas
2,
Vida Malinauskienė
1,
Frank A. Sløk
3 and
Algirdas Šačkus
1,2
1
Department of Organic Chemistry, Kaunas University of Technology, Radvilėnų pl. 19, LT-50254 Kaunas, Lithuania
2
Institute of Synthetic Chemistry, Kaunas University of Technology, K. Baršausko g. 59, LT-51423 Kaunas, Lithuania
3
Vipergen ApS, 23A Gammel Kongevej, V DK-1610 Copenhagen, Denmark
*
Author to whom correspondence should be addressed.
Molbank 2021, 2021(2), M1207; https://doi.org/10.3390/M1207
Submission received: 16 April 2021 / Revised: 28 April 2021 / Accepted: 29 April 2021 / Published: 1 May 2021
(This article belongs to the Special Issue Heteroatom Rich Organic Heterocycles)

Abstract

:
Methyl 2-amino-4-[1-(tert-butoxycarbonyl)azetidin-3-yl]-1,3-selenazole-5-carboxylate as a newly functionalized heterocyclic amino acid was obtained via [3+2] cycloaddition. The structure of the novel 1,3-selenazole was unequivocally confirmed by detailed 1H, 13C, 15N, and 77Se NMR spectroscopic experiments, HRMS and elemental analysis.

1. Introduction

Selenium is an essential bio-trace element that plays an important role in antioxidant selenoproteins for protection against oxidative stress in humans and other animal species [1]. Functionalized organoselenium compounds possess a wide range of biological activities and are present in many pharmacologically important substances [2]. Well-known representative bioactive molecules that contain selenium in their structure are potent the antiviral agent selenazofurin [3], histamine H2-agonist known as amselamine [4], as well as ebselen and its analogues exhibiting anti-inflammatory, antioxidant, and cytoprotective properties [5,6]. Moreover, the synthesis of new Se-containing β-lactams such as selenapenam, selenacepham and selenazepine as a potential antibacterial agents has been reported [7] (Figure 1).
On the other hand, the azetidine ring has been identified as a conformationally restricted component of important pharmacological molecules [8], including synthetic analogues of natural amino acids, such as γ-aminobutyric acid (GABA) [9]. The azetidine ring is also present in the molecular structure of the well-known antihypertensive drug azelnidipine (Figure 2) [10].
The aim of the present study was to extend our previous work on heterocyclic amino acids containing selenazole and azetidine cores [11,12,13,14], as it is still a new and potentially relevant field. In this work, a molecular system containing both selenazole and azetidine scaffolds was synthesized through Hantzsch cyclization of β-ketoester.

2. Results and Discussion

Selenazoles can be obtained using analogous synthetic strategies similar to the ones used for thiazoles. Among a variety of ring construction reactions, the most widely used approach is Hantzsch synthesis and its variations [15,16,17]. This methodology reliably leads to the formation of diverse heterocyclic rings in good yields.
The synthetic strategy for obtaining novel selenazole-azetidine building blocks is outlined in Scheme 1. The target compound was synthesized in four steps using commercially available N-Boc-protected azetidine-3-carboxylic acid 1. The synthetic sequence was started with preparation of β-ketoester 2 by its adduct methanolysis with Meldrum’s acid. In the following step, bromination of ester 2 was carried out in the presence of NBS in acetonitrile. The reaction afforded an α-bromocarbonyl compound 3, which was immediately used in the final step. The condensation of 3 with selenourea afforded the desired methyl 2-amino-4-[1-(tert-butoxycarbonyl)azetidin-3-yl]-1,3-selenazole-5-carboxylate 4.
The final structure of compound 4 was easily deduced after a detailed analysis of spectral data (Figures S1–S8). The 1H-15N HSQC experiment revealed that the most downfield protons at 7.25 ppm belong to the NH2 group, which resonates at −294.6 ppm. The multiplicity-edited 1H-13C HSQC spectrum revealed a cross-peak correlating a methine proton at 4.67 ppm with the 13C signal at 28.1 ppm from the azetidine ring (Figure 3).
The connectivity of the 2-amino-1,3-selenazole-5-carboxylate moiety and the N-Boc-protected azetidine fragment could be confirmed based on long-range 1H-13C and 1H-15N correlations, obtained from gs-HMBC spectra of the aforementioned protons. The 1H-15N HMBC experiment revealed a strong three-bond correlation between the 1,3-selenazole N-3 nitrogen, which resonated at −128.1 ppm, and the protons from the 2-amino functional group. In the case of 3-H from the azetidine ring system, it showed a strong correlation with the selenazole N-3, and additionally revealed data for azetidine N-1 at −309.0 ppm. The data from 1H–13C HMBC and LR-HSQMBC experiments allowed an unambiguous assignment of the 1,3-selenazole ring system, as we were able to easily distinguish the carbonyl carbons from the N-Boc and carboxylate moieties. Lastly, the protonated azetidine carbon C-3 at 21.8 ppm showed a correlation with an adjacent selenazole quaternary carbon C-4 at 162.2 ppm in the 1,1-ADEQUATE spectrum. By a process of elimination, this allowed the assignment of the last selenazole C-2 signal, which resonated at 173.6 ppm. The 77Se NMR spectra contained a singlet at 581.4 ppm. The observed 15N and 77Se chemical shifts are consistent with data reported in the literature for 1,3-selenazoles possessing similar structures [18].
The optical properties of compound 4 were investigated by UV/vis spectroscopy. The electronic absorption spectra of compound 4 in tetrahydrofuran (THF) contained an intense absorption band at 314 nm. Fluorescence spectra displayed an emission maximum at 375 nm (Figure 4).

3. Materials and Methods

3.1. General

All chemicals and solvents were purchased from Sigma-Aldrich (St. Louis, MO, USA) and used without further purification unless otherwise specified. Prior to use, dichloromethane (DCM) was stored over molecular sieves (4 Å). Reaction progress was monitored by thin-layer chromatography (TLC) analysis on Macherey–Nagel™ ALUGRAM® Xtra SIL G/UV254 plates (Macherey−Nagel™, Düren, Germany). TLC plates were visualized with ultraviolet (UV) light (wavelength 254 nm). Compounds were purified by flash chromatography in a glass column (stationary phase—silica gel, high-purity grade 9385, pore size 60 Å, particle size: 230–400 mesh, Sigma-Aldrich, St. Louis, MO, USA). The 1H, 13C and 15N-NMR spectra were recorded in chloroform-D (CDCl3) at 25 °C on a Bruker Avance III 700 (700 MHz for 1H, 176 MHz for 13C, 71 MHz for 15N) spectrometer equipped with a 5 mm TCI 1H-13C/15N/D z-gradient cryoprobe (Bruker BioSpin AG, Fallanden, Switzerland). 77Se NMR spectra (76.31 MHz, absolute referencing via Ξ ratio) were obtained on a Bruker Avance III 400 (Bruker BioSpin AG, Fallanden, Switzerland) instrument with a ‘directly’ detecting broadband observe probe (BBO). The chemical shifts, expressed in ppm, were relative to tetramethylsilane (TMS). The 15N NMR spectrum was referenced to neat, external nitromethane (coaxial capillary). The full and unambiguous assignments of the 1H, 13C, 15N, and 77Se-NMR resonances were achieved using standard Bruker software (TopSpin 3.5.6, Bruker BioSpin AG, Fallanden, Switzerland) and a combination of standard NMR spectroscopic techniques, such as distortionless enhancement by polarization transfer (DEPT), homonuclear correlation spectroscopy (COSY), gradient-selected heteronuclear single quantum coherence (gs-HSQC), gradient-selected heteronuclear multiple bond correlation (gs-HMBC), heteronuclear 2-bond correlation (H2BC), long-range heteronuclear single-quantum multiple-bond correlation (LR-HSQMBC) and 1,1-ADEQUATE experiments. The infrared (IR) spectra were recorded on a Bruker TENSOR 27 spectrometer (Bruker Optik GmbH, Ettlingen, Germany) using potassium bromide (KBr) pellets. The melting point was determined in open capillary tubes with a DigiMelt MPA160 apparatus (temperature gradient: 1 °C/min) and was uncorrected. The HRMS spectrum was obtained in electrospray ionization (ESI) mode on a Bruker MicrOTOF-Q III spectrometer (Bruker Daltonik GmbH, Bremen, Germany). Elemental analysis (C, H and N) was determined using a CE-440 Elemental Analyzer (Exeter Analytical Ltd, Coventry, UK), Model 440 CHN/O/S. The UV/vis spectrum was recorded using 10−4 M solution of the compound in THF on a Shimadzu 2600 UV/vis spectrometer (Shimadzu EUROPA GmbH, Duisburg, Germany). The fluorescence spectrum was recorded on a FL920 fluorescence spectrometer from Edinburgh Instruments (Edinburg Instruments Ltd, Livingston, UK).

3.2. Synthesis

1-Boc-azetidine-3-carboxylic acid 1 (3.267 g, 16.2 mmol), Meldrum‘s acid (2.811 g, 19.5 mmol), DMAP (2.969 g, 24.3 mmol) and EDC (3.738 g, 19.5 mmol) were dissolved in DCM (70 mL). The resulting mixture was stirred at room temperature for 18 h. The reaction mixture was diluted with an additional volume of DCM (50 mL) and washed with 10% KHSO4 aqueous solution (3 × 50 mL) and brine (1 × 100 mL). The organic layer was separated, dried over anhydrous Na2SO4, filtered, and the solvent was evaporated under reduced pressure. The residue was dissolved in MeOH (70 mL) and stirred at 60 °C for 18 h. The solvent was evaporated in vacuo. The residue was purified by column chromatography on silica gel (n-hexane/ethyl acetate, gradient from 6:1 to 1:1 v/v). Obtained β-ketoester 2 (3.458 g, 13.4 mmol) was dissolved in ACN (100 mL) and NBS (3.588 g, 20.2 mmol) was added. The reaction mixture was stirred at room temperature for 2 h. After the reaction, the solvent was removed under reduced pressure. The residue was dissolved in EtOAc (50 mL) and filtered through a pad of silica. The filter pad was washed out with EtOAc (150 mL). The filtrate was concentrated in vacuo. The residue was dissolved in MeOH (40 mL) and selenourea (0.915 g, 7.4 mmol) was added. The reaction mixture was stirred at room temperature. After 2 h, the resulting mixture was added dropwise to 2% Na2CO3 aqueous solution (100 mL) while stirring. The precipitate was filtered and dissolved in DCM (100 mL). The solution was dried over anhydrous Na2SO4, filtered, and the solvent was removed in vacuo. The residue was purified by column chromatography on silica gel (n-hexane/ethyl acetate, gradient from 4:1 to 1:1 v/v) to afford compound 4. The obtained solid was recrystallized from hexane. Colorless crystals (683 mg) were obtained with an overall of yield 21%. Rf = 0.19 (n-hexane/ethyl acetate 2/1, v/v), m.p. 167−168 °C. IR (KBr) νmax, cm−1: 3388 (NH), 3293 (NH), 3175, 2975, 2955, 2890, 1680 (C=O), 1628 (C=O), 1505, 1415, 1284, 1139, 1067, 909, 772 and 757, 527. 1H NMR (700 MHz, CDCl3) δ, ppm: 1.47 (9H, s, 3 × CH3), 3.75 (3H, s, OCH3), 4.01 (2H, br s, 2 × CHaHb), 4.20−4.27 (2H, m, 2 × CHaHb), 4.67 (1H, tt, J = 8.7, 5.5 Hz, CH), 7.25 (2H, s, NH2). 13C NMR (176 MHz, CDCl3) δ, ppm: 28.1 (CH), 28.5 (3 × CH3), 51.8 (OCH3), 53.6 (CH2), 55.1 (CH2), 79.9 (C(CH3)3), 113.8 (Sel C-5), 156.6 (Boc C=O), 162.2 (Sel C-4), 164.0 COOCH3), 173.6 (Sel C-2). 15N NMR (71 MHz, CDCl3) δ, ppm: −309.0 (Az N-1), −294.6 (NH2), −128.1 (Sel N-3). 77Se NMR (76 MHz, CDCl3) δ, ppm: 581.4. HRMS (ESI) for C13H19N3NaO4Se ([M + Na]+): found m/z 384.0434, calculated m/z 384.0434. Elem. An. for C13H19N3O4Se (%): found C, 43.87; H, 5.33; N, 11.22; calculated C, 43.34; H, 5.32; N, 11.66.

4. Conclusions

In this short note, we reported the synthesis and structure elucidation of methyl 2-amino-4-[1-(tert-butoxycarbonyl)azetidin-3-yl]-1,3-selenazole-5-carboxylate 4. This compound is a valuable building block for more complex molecular systems as well as for the development of DNA-encoded chemical libraries.

Supplementary Materials

The following are available online: NMR, HRMS, and IR spectra of compound 4. Figure S1: 1H NMR spectrum of compound 4. Figure S2: 13C NMR spectrum of compound 4. Figure S3: 1H-15N HSQC NMR spectrum of compound 4. Figure S4: The overlaid 1H-13C gs-HSQC and gs-HMBC NMR spectra of compound 4. Figure S5: 1H-15N HMBC NMR spectrum of compound 4. Figure S6: 1H-13C 2 Hz LR-HSQMBC NMR spectra of compound 4. Figure S7: The overlaid 1H-13C gs-HSQC (red) and 60 Hz 1,1-ADEQUATE (black) NMR spectra of compound 4. Figure S8: 77Se NMR spectrum of compound 4. Figure S9: IR spectrum of compound 4. Figure S10: HRMS spectrum of compound 4.

Author Contributions

Conceptualization, F.A.S. and A.Š.; methodology, K.D.; validation, V.M.; formal analysis, K.D., P.V. and A.B.; investigation, K.D., P.V. and A.B.; resources, F.A.S.; data curation, P.V. and A.B.; writing—original draft preparation, K.D., A.B., A.Š. and V.M.; writing—review and editing, V.M. and A.Š.; visualization, A.B.; supervision, A.Š. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Vipergen ApS company (Copenhagen, Denmark).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Tinggi, U. Selenium: Its role as antioxidant in human health. Environ. Health Prev. Med. 2008, 13, 102–108. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Nogueira, C.W.; Zeni, G.; Rocha, J.B.T. Organoselenium and organotellurium compounds: Toxicology and pharmacology. Chem. Rev. 2004, 104, 6255–6285. [Google Scholar] [CrossRef] [PubMed]
  3. Qiao, J.; Liu, Y.; Du, Y. Method to build 2,4-substituted selenazole from β-azido diselenide and carboxylic acid: A formal synthesis of selenazofurin. Tetrahedron 2018, 74, 3061–3068. [Google Scholar] [CrossRef]
  4. van der Goot, H.; Eriks, J.C.; Leurs, R.; Timmerman, H. Amselamine, a new selective histamine H2-receptor agonist. Bioorg. Med. Chem. Lett. 1994, 4, 1913–1916. [Google Scholar] [CrossRef]
  5. Sarma, B.K.; Mugesh, G. Glutathione peroxidase (GPx)-like antioxidant activity of the organoselenium drug ebselen: Unexpected complications with thiol exchange reactions. J. Am. Chem. Soc. 2005, 127, 11477–11485. [Google Scholar] [CrossRef] [PubMed]
  6. Angeli, A.; Trallori, E.; Ferraroni, M.; Mannelli, L.D.C.; Ghelardini, C.; Supuran, C.T. Discovery of new 2, 5-disubstituted 1,3-selenazoles as selective human carbonic anhydrase IX inhibitors with potent anti-tumor activity. Eur. J. Med. Chem. 2018, 157, 1214–1222. [Google Scholar] [CrossRef] [PubMed]
  7. Ninomiya, M.; Garud, D.R.; Koketsu, M. Biologically significant selenium-containing heterocycles. Coord. Chem. Rev. 2011, 255, 2968–2990. [Google Scholar] [CrossRef]
  8. Brandi, A.; Cicchi, S.; Cordero, F.M. Novel syntheses of azetidines and azetidinones. Chem. Rev. 2008, 108, 3988–4035. [Google Scholar] [CrossRef] [PubMed]
  9. Faust, M.R.; Höfner, G.; Pabel, J.; Wanner, K.T. Azetidine derivatives as novel γ-aminobutyric acid uptake inhibitors: Synthesis, biological evaluation, and structure-activity relationship. Eur. J. Med. Chem. 2010, 45, 2453–2466. [Google Scholar] [CrossRef] [PubMed]
  10. Sada, T.; Saito, H. Pharmacological profiles and clinical effects of azelnidipine, a long-acting calcium channel blocker. Folia Pharmacol. Jpn. 2003, 122, 539–547. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Malinauskienė, V.; Dzedulionytė, K.; Bieliauskas, A.; Burinskas, S.; Sløk, F.A.; Šačkus, A. L-Proline and related chiral heterocyclic amino acids as scaffolds for the synthesis of functionalized 2-amino-1,3-selenazole-5-carboxylates. Chem. Heterocycl. Compd. 2018, 54, 469–473. [Google Scholar] [CrossRef]
  12. Iškauskienė, M.; Ragaitė, G.; Sløk, F.A.; Šačkus, A. Facile synthesis of novel amino acid-like building blocks by N-alkylation of heterocyclic carboxylates with N-Boc-3-iodoazetidine. Mol. Divers. 2020, 24, 1235–1251. [Google Scholar] [CrossRef] [PubMed]
  13. Žukauskaitė, A.; Mangelinckx, S.; Buinauskaitė, V.; Šačkus, A.; De Kimpe, N. Synthesis of new functionalized aziridine-2- and azetidine-3-carboxylic acid derivatives of potential interest for biological and foldameric applications. Amino Acids 2011, 41, 541–558. [Google Scholar] [CrossRef] [PubMed]
  14. Mangelinckx, S.; Žukauskaitė, A.; Buinauskaitė, V.; Šačkus, A.; De Kimpe, N. Synthesis of alkyl 2-(bromomethyl)aziridine-2-carboxylates and alkyl 3-bromoazetidine-3-carboxylates as amino acid building blocks. Tetrahedron Lett. 2008, 49, 6896–6900. [Google Scholar] [CrossRef]
  15. Facchinetti, V.; Avellar, M.M.; Nery, A.C.S.; Gomes, C.R.B.; Vasconcelos, T.R.A.; De Souza, M.V.N. An Eco-friendly, Hantzsch-Based, Solvent-Free Approach to 2-Aminothiazoles and 2-Aminoselenazoles. Synthesis 2016, 48, 437–440. [Google Scholar] [CrossRef]
  16. Kuarm, B.S.; Rajitha, B. Xanthan sulfuric acid: An efficient, biosupported, and recyclable solid acid catalyst for the synthesis of 4,4-(arylmethylene)bis(1H-pyrazol-5-ols). Synth. Commun. 2012, 42, 2382–2387. [Google Scholar] [CrossRef]
  17. Kanapickaitė, V.; Martynaitis, V.; Šačkus, A. Facile synthesis of novel functionalized 1,3-selenazoles. Arkivoc 2009, 11, 268–276. [Google Scholar] [CrossRef]
  18. Duddeck, H.; Bradenahl, R.; Stefaniak, L.; Jazwinski, J.; Kamienski, B. Synthesis and multinuclear magnetic resonance investigation of some 1,3-selenazole and 1,3-selenazoline derivatives. Magn. Reson. Chem. 2001, 39, 709–713. [Google Scholar] [CrossRef]
Figure 1. Biologically active organoselenium compounds.
Figure 1. Biologically active organoselenium compounds.
Molbank 2021 m1207 g001
Figure 2. Structure of azelnidipine.
Figure 2. Structure of azelnidipine.
Molbank 2021 m1207 g002
Scheme 1. Synthesis of methyl 2-amino-4-[1-(tert-butoxycarbonyl)azetidin-3-yl]-1,3-selenazole-5-carboxylate (4). Reagents and conditions: (i) Meldrum’s acid, DMAP, EDC, DCM, r.t., 18 h; (ii) MeOH, 60 °C, 18 h; (iii) NBS, ACN, r.t., 2 h; (iv) selenourea, MeOH, r.t., 2 h.
Scheme 1. Synthesis of methyl 2-amino-4-[1-(tert-butoxycarbonyl)azetidin-3-yl]-1,3-selenazole-5-carboxylate (4). Reagents and conditions: (i) Meldrum’s acid, DMAP, EDC, DCM, r.t., 18 h; (ii) MeOH, 60 °C, 18 h; (iii) NBS, ACN, r.t., 2 h; (iv) selenourea, MeOH, r.t., 2 h.
Molbank 2021 m1207 sch001
Figure 3. Relevant 1,1-ADEQUATE, 1H-13C HMBC, 1H-15N HMBC, 1H-13C LR-HSQMBC correlations and 1H NMR (in italics), 15N NMR (in bold), 77Se (in bold, underlined) and 13C-NMR chemical shifts of compound 4.
Figure 3. Relevant 1,1-ADEQUATE, 1H-13C HMBC, 1H-15N HMBC, 1H-13C LR-HSQMBC correlations and 1H NMR (in italics), 15N NMR (in bold), 77Se (in bold, underlined) and 13C-NMR chemical shifts of compound 4.
Molbank 2021 m1207 g003
Figure 4. Absorption and emission (λex = 320 nm) spectrum of compound 4 in THF.
Figure 4. Absorption and emission (λex = 320 nm) spectrum of compound 4 in THF.
Molbank 2021 m1207 g004
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Dzedulionytė, K.; Voznikaitė, P.; Bieliauskas, A.; Malinauskienė, V.; Sløk, F.A.; Šačkus, A. Methyl 2-Amino-4-[1-(tert-butoxycarbonyl)azetidin-3-yl]-1,3-selenazole-5-carboxylate. Molbank 2021, 2021, M1207. https://doi.org/10.3390/M1207

AMA Style

Dzedulionytė K, Voznikaitė P, Bieliauskas A, Malinauskienė V, Sløk FA, Šačkus A. Methyl 2-Amino-4-[1-(tert-butoxycarbonyl)azetidin-3-yl]-1,3-selenazole-5-carboxylate. Molbank. 2021; 2021(2):M1207. https://doi.org/10.3390/M1207

Chicago/Turabian Style

Dzedulionytė, Karolina, Paulina Voznikaitė, Aurimas Bieliauskas, Vida Malinauskienė, Frank A. Sløk, and Algirdas Šačkus. 2021. "Methyl 2-Amino-4-[1-(tert-butoxycarbonyl)azetidin-3-yl]-1,3-selenazole-5-carboxylate" Molbank 2021, no. 2: M1207. https://doi.org/10.3390/M1207

APA Style

Dzedulionytė, K., Voznikaitė, P., Bieliauskas, A., Malinauskienė, V., Sløk, F. A., & Šačkus, A. (2021). Methyl 2-Amino-4-[1-(tert-butoxycarbonyl)azetidin-3-yl]-1,3-selenazole-5-carboxylate. Molbank, 2021(2), M1207. https://doi.org/10.3390/M1207

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop